Treatment of PTSD by Reduction of Traumatic Memory Reconsolidation by Propranolol : a Multisite Trial (REDUCTRAUMA2)
|Post-traumatic Stress Disorder||Drug: Propranolol Other: Trauma reactivation Drug: placebo||Phase 2|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator
Primary Purpose: Treatment
|Official Title:||Treatment of PTSD by Reduction of Traumatic Memory Reconsolidation by Propranolol : a Multisite Trial|
- PTCD CheckList (PCL) total score. [ Time Frame: difference between week 1 (before administration of the study medication) and week 7 (one week after the last intake of study medication) ]
|Study Start Date:||November 2012|
|Estimated Study Completion Date:||November 2017|
|Estimated Primary Completion Date:||May 2017 (Final data collection date for primary outcome measure)|
Experimental: Propranolol + reactivation
they have a script-driven mental imagery of the traumatic event white drug
Other: Trauma reactivation
Trauma reactivation: script-driven mental imagery of the traumatic event
Placebo Comparator: Placebo + reactivation
They have a script-driven mental imagery of the traumatic event with placebo
Other: Trauma reactivation
Trauma reactivation: script-driven mental imagery of the traumatic eventDrug: placebo
Post-traumatic stress disorder (PTSD) develops following an exposure to a life threatening event. One of the characteristic features of PTSD is the recurrence of intrusive memories of an experienced trauma. The persistence of disturbing traumatic memories in PTSD is often explained in terms of a trauma-induced enhancement of memory encoding. Several studies indicate that an increased noradrenergic activity during trauma enhances the encoding of memory. Elevated levels of norepinephrine in the cerebrospinal fluid of individuals with PTSD and the correlation of this elevation with the severity of PTSD symptoms suggest that increased noradrenergic activity is also involved in the maintenance of PTSD symptoms. Reactivation of memory by retrieval also renders the memory labile and susceptible to treatments. This latter process is referred to as memory reconsolidation. Consolidation and reconsolidation both occur within a distinct time window following new learning (in consolidation) and/or retrieval (in reconsolidation). Even well-consolidated old fear memories undergo reconsolidation and may be disrupted by means of pharmacological manipulation. Propranolol may be effective in treating PTSD long after symptoms have been consolidated. Propranolol given after reactivation of the memory of a past traumatic event reduces physiologic responding during subsequent mental imagery of the event.
HYPOTHESE: Subjects with chronic PTSD who receive propranolol before trauma evocation will subsequently show decreased PTSD symptoms, compared to subjects who receive a placebo.
METHOD: 56 participants with chronic PTSD will be recruited for participation. On Week 1, the subjects will complete a standardized measure of PTSD symptoms. Next, 90 minutes after the administration of the study medication (either propranolol or placebo), participants will undergo a script preparation procedure, during which they will disclose details of their traumatic event. Scripts portraying this event will be prepared for subsequent replay.
On Week 2, after the administration of the study medication (either propranolol or placebo), participants will be asked (reading the script) to engaged in a script-driven mental imagery of the traumatic event. Following this procedure, PTSD symptoms will be assessed.
The same procedure will be repeated on Weeks 3, 4, 5 and 6. On Weeks 7 and 18, the standardized measure of PTSD symptoms will be repeated.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01713556
|Contact: Philippe BIRMES, MD||05 61 77 25 firstname.lastname@example.org|
|Centre Hospitalier Charles Perrens||Not yet recruiting|
|Bordeaux, France, 33076|
|Contact: Bruno AOUIZERATE, PHD 05-56-56-35-85 email@example.com|
|Principal Investigator: bruno AOUZERATE, PHD|
|Lille, France, 59037|
|Contact: Guillaume VAIVA, PHD 03.20.44.43.83 firstname.lastname@example.org|
|Principal Investigator: Guillaume VAIVA, PHD|
|Chu Montpellier||Not yet recruiting|
|Montpellier, France, 34295|
|Contact: Jérôme ATTAL, PHD 04 67 33 97 18 email@example.com|
|Principal Investigator: jerome ATTAL, PHD|
|Toulouse, France, 31000|
|Contact: Philippe BIRMES, PHD 05 61 77 25 81 firstname.lastname@example.org|
|Principal Investigator: Philippe BIRMES, PHD|
|Principal Investigator:||Philippe BIRMES, MD||University Hospital, Toulouse|